While early studies of BRAF inhibitors demonstrated anti-tumor activity in advanced thyroid cancers harboring the BRAF V600E mutation, subsequent experience and research showed limited long-term disease control due to abundant compensatory mechanisms. This evidence concerns the gene BRAF and thyroid cancer.